The long QT syndrome type 2 (LQT2) is inheritable life threatening arrhythmic disorder and one of the most common genetic variants in long QT syndrome. There are some indications for treatment of the patients with LQT2 but it is impossible to completely prevent fatal arrhythmia. To develop novel therapy for the patients with LQT2, it has been desired to generate diseasespecific and patient-spec...

OBJECTIVE To study the complementary value of information from functional capacity evaluation (FCE) for insurance physicians (IPs) who assess the physical work ability of claimants with long-term musculoskeletal disorders (MSD). METHOD A post-test only design was used in the context of disability claims. Twenty-eight IPs participated in the study. Claimants with MSD formed the patient populat...

when induced pluripotent stem (iPs) cells were first discovered in 2007 there was a huge interest.1,2 The iPs cell technique with a minimal number of embryonic transcription factors could turn skin or any other tissue directly into viable embryonic stem cells. it was amazing to able to so simply to turn mature adult cells back into embryonic stem cells. The discovery also avoided the most diffi...

Ischemic stroke is a leading cause of human death and disability while clinical treatments are limited. The adult brain possesses endogenous regenerative activities that may benefit tissue repair after stroke. Trophic factors such as stromal cell-derived factor 1 alpha (SDF-1α) are upregulated in the ischemic brain, which promote endogenous regeneration. The regenerative response, however, is n...

Induced pluripotent stem (iPS) cells have been generated from mouse and human fibroblasts by the retroviral transduction of four transcription factors. However, the cell origins and molecular mechanisms of iPS cell induction remain elusive. This report describes the generation of iPS cells from adult mouse hepatocytes and gastric epithelial cells. These iPS cell clones appear to be equivalent t...

The recent development of induced pluripotent stem (iPS) cell technology brings cell and gene therapies to patients one large step closer to reality. Technical improvements in various research fields sometimes come together fortuitously, leading to approaches to treating disease. If iPS cell technology continues to progress smoothly as expected and is actually applied to patients, the next logi...

In this paper, we study the strength of aggregation cuts for sign-pattern integer programs (IPs). Sign-pattern IPs are a generalization of packing IPs and are of the form {x ∈ Z+ | Ax ≤ b} where for a given column j, Aij is either non-negative for all i or non-positive for all i. Our first result is that the aggregation closure for such sign-pattern IPs can be 2-approximated by the original 1-r...

Nuclear reprogramming enables patient-specific derivation of induced pluripotent stem (iPS) cells from adult tissue. Yet, iPS generation from patients with type 2 diabetes (T2D) has not been demonstrated. Here, we report reproducible iPS derivation of epidermal keratinocytes (HK) from elderly T2D patients. Transduced with human OCT4, SOX2, KLF4 and c-MYC stemness factors under serum-free and fe...

Human induced pluripotent stem (iPS) cells have been generated from various cell types including blood cells, and offer certain advantages as a starting population for reprogramming postnatal somatic cells. Unlike adult stem cells, iPS cells can proliferate limitlessly in culture while retaining their potential to differentiate into any cell type, including hematopoietic lineages. Derivation of...